Seminar

Date and Time	Details
17.02.2025 at 4:15 p.m., TU Dortmund, CDI 120	To be announced Prof. Manuela Zucknick, Department of Biostatistics, Faculty of Medicine, University of Oslo, Sweden
27.01.2025 at 4:15 p.m., TU Dortmund, CDI 120	To be announced Hannah Klinkhammer, M. Sc., PhD Student at Institut für Medizinische Biometrie, Informatik und Epidemiologie (IMBIE), Universität Bonn
20.01.2025 at 4:15 p.m., TU Dortmund, CDI 120	To be announced Andrew Hooker, Ph.D., Professor of Pharmacometrics, Department of Pharmacy; Pharmacometrics, Uppsala University, Sweden
24.06.2024 at 4:15 p.m., TU Dortmund, CDI 120	(Joint) Modelling approaches for lung function decline and risk of death for cystic fibrosis patients Prof. Dr. Elisabeth Bergherr, Chair of Spatial Data Science and Statistical Learning, Georg-August-Universität Göttingen
22.04.2024 at 4:15 p.m., TU Dortmund, CDI 120	Multiple Endpoints and Prioritized Outcomes: Effects and Nonparametric Analysis Methods Prof. Dr. Edgar Brunner, Emeritus, Department of Medical Statistics, Universitätsmedizin Göttingen The analysis of multiple and composite endpoints in medical and biological trials is discussed since many years. Numerous procedures have been developed for different situations and statistical models. Composite endpoints are suggested to combine several outcomes into one single endpoint which can be evaluated by a simple analysis. The danger, however, when using a combined endpoint is that the failure of an effect in an important clinical outcome may be masked by a large effect of a less important clinical outcome. Therefore, it has been suggested to prioritize the outcomes and if the outcome of a patient in the treatment group is better than that of a patient in the control group then score 1 is assigned or score 0 if it is worse. In case of no difference then one steps down to the next important outcome until no difference is found in the last important endpoint resulting in score ½. This handling of prioritized outcomes has been suggested by Buyse (2010) who called this procedure ‘generalized pairwise comparisons’ (GPC) since all pairs of patients from the treatment and the control group are compared by prioritizing the components. The resulting statistical procedure is closely related to the Mann-Whitney statistic. To understand the advantages, drawbacks, and limitations of the GPC, the relations to rank procedures and U-statistics are presented and discussed. The practical use and the interpretation are demonstrated my means of examples. Buyse M. Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. StatMed. 2010; 3245- 3257.
26.02.2024 at 4:15 p.m., TU Dortmund, CDI 120	Allelic expression imbalance to uncover disease-relevant gene regulation Associate Professsor Michael I. Love, PhD, UNC School of Medicine Genetics, Chapel Hill, USA Genome-wide association studies (GWAS) have identified tens of thousands of genomic loci that are associated with complex traits or diseases, many of which are located in non-coding regulatory regions. One potential mechanism by which allelic variation in these non-coding regions may affect phenotypes is that the variants may influence transcription in cis. A non-coding region that affects local transcription may be referred to as a cis-regulatory element (CRE). Individuals that are heterozygous at variants in CRE may exhibit imbalanced allelic expression at the regulated genes. With RNA-sequencing (RNA-seq) experiments, it is possible to observe such imbalance in allelic expression in the sequenced reads for those individuals also heterozygous for a variant in the exons of a regulated gene. In this talk I will give an overview of methods for detecting AEI from existing short-read RNA-seq data, and how new technologies will help in this task.
12.02.2024 at 4:15 p.m., TU Dortmund, CDI 120	Sample size planning for multiple contrast test Anna Pöhlmann, Institute for Biometrics and Clinical Epidemiology, Charité Berlin
22.01.2024 at 4:15 p.m., TU Dortmund, via Zoom	Phases of development for statistical methods Dr. Tim Morris, Principal Research Fellow MRC Clinical Trials Unit at UCL Applied researchers need to be able to make informed decisions about which methods to use when. Research into statistical methods should thus provide an evidence-base that facilitates this. Unfortunately, the appetite of funders and journal editors for novelty and innovation in statistical methodology means the evidence base is often sparse. How should a method be developed and evaluated to go from ‘neat idea’ to trustworthy? We should be able to say when to use and avoid it, and how to make decisions for the study at hand. By analogy to the familiar phases of drug-development, I will outline four ‘phases’ of research for statistical methods. This framework helps us consider the contribution of a piece of statistical research to our overall understanding. The aims of this view are to: 1. Help frustrated methodological researchers understand why their method has not been universally adopted; 2. Legitimise ‘late-phase’ statistical methods research; 3. Give applied researchers a way to articulate their hesitation about new methods. I will give a few examples to illustrate, note some difficulties, and leave time for discussion.
15.01.2024 at 4:15 p.m., TU Dortmund, CDI 120	Methods for the meta-analysis of ROC curves – A statistical challenge Prof. Dr. Annika Hoyer, Head of Biostatistics and Medical Biometry Bielefeld University
08.01.2024 at 4:15 p.m., TU Dortmund, via Zoom	Insights into the world of a CMC statistician Dr. Beate Presser, Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach This presentation provides insights into the life of a CMC (Chemistry, Manufacturing, and Controls) statistician in the pharmaceutical industry, elucidating statistical questions and their solutions through various examples. These examples range from the concrete implementation of an ICH Q14 guideline on the development of analytical methods with DoE (design of experiment) to examples from the field of process modeling and unplanned data. Different model types are explained in practical examples.
30.10.2023 at 4:15 p.m., TU Dortmund, CDI 120	Statistical Planning and Analysis of Translational Trials Frank Konietschke, Acting Head of the Institute, Head of the Statistical Methods of Translation and Early Clinical Trials , Charité Berlin
23.10.2023 at 4:15 p.m., TU Dortmund, CDI 120	How to better detect differentially expressed proteins when the sample size is small Kai Kammers, Assistant Professor of Oncology, Johns Hopkins Medicine
17.07.2023 at 4:15 p.m., TU Dortmund, CDI 120	Sparse group models for leveraging pleiotropy effects from GWAS Benoit Liquet-Weiland, Professor of Mathematical and Computational Statistics, School of Mathematical and Physical Sciences, Macquarie University
26.06.2023 at 4:15 p.m., TU Dortmund, via Zoom	Talk 1: Use of Environmental Mixture Methodology in Epidemiology Studies Talk 2: Constructing DNA methylation risk scores for mediation analysis Grace Christensen and Junyu Chen, MPH PhD Candidate Emory University’s Rollins School of Public Health
12.06.2023 at 4:15 p.m., TU Dortmund, via Zoom	Talk 1: EFSA’s guidance on the use of the BMD approach in risk assessment Talk 2: The statistical methodology behind EFSA’s BMD platform Talk 3: Illustration of EFSA’s new BMD analysis platform Prof. Dr. Marc Aerts, Hasselt University Belgium, and Dr. José Cortiñas Abrahantes, EFSA European Food Safety Authority
22.05.2023 at 4:15 p.m., TU Dortmund, CDI 120	Efficient Designs for toxicological experiments Weng Kee Wong, Professor at the Department of Biostatistics, University of California, Los Angeles I first discuss the importance and challenges in toxicology problems, which are increasingly pervasive in our daily lives. A main focus of the talk is how to implement more informative designs in the laboratory that will likely lead to more accurate statistical inference. Optimal experimental design theory and ideas will be used to construct model-based optimal designs for a variety of common nonlinear models used in toxicology and I will present efficient designs to estimate model parameters, or, one or more functions of the model parameters, including optimal designs to identify thresholds, detect presence of hormesis, and in identifying an adequate model among several postulated models. In addition, I will discuss metaheuristics as general optimization tools to find optimal designs for more complex problems and demonstrate how to them in web-based tools to find optimal designs. If time permits, I will also discuss one of my current work in toxicology that concerns Haber’s law.
18.04.2023 at 4:15 p.m., TU Dortmund, ME21	How does air pollution effect our brain? The complex relationship between environmental, social and epigenetic factors? Anke Huels, Assistant Professor, Department of Epidemiology and Gangarosa Departmentof Environmental Health, Rollins School of Public Health, Emory University, Atlanta, USA
03.04.2023 at 4:15 p.m., TU Dortmund, CDI 120	Prediction Intervals for overdispersed Poisson data Dr. Max Menssen, Institute of Cell Biology and Biophysics, Leibniz Universität Hannover
23.01.2023 at 4:15 p.m., TU Dortmund, via Zoom	Novel clinical trial designs for precision oncology: Prof. Dr. Annette Kopp-Schneider, Deutsches Krebsforschungszentrum in der Helmholtz-Gemeinschaft, Heidelberg The aim of precision oncology is to provide a targeted therapy for each individual tumor. To reach this goal, it is necessary to identify in each patient actionable biomarkers and to determine a matched targeted therapy for the specific biomarker(s). Clinical trials are necessary to investigate whether the biomarker-treatment combination in fact has the desired effect. Due to the large number of possible biomarker-treatment combinations, and due to the small patient numbers matching such a combination, classical clinical phase III trials are not feasible in this situation. Precision oncology therefore requires the development of novel trials designs. We will discuss the concepts of basket, umbrella and platform designs for precision oncology and will present the challenges for the statistical analysis in these trial designs. Bayesian methods are naturally suited for precision oncology clinical trials as they allow for more flexible designs and they are suited for incorporation of external information and for borrowing of information between arms of clinical trials. We will discuss the use of Bayesian methods for clinical trials and present some current developments.
16.01.2023 at 4:15 p.m., TU Dortmund, CDI 120	Optimal test procedures for multiple hypotheses controlling the familywise expected loss Prof. Dr. Frank Bretz, Novartis Pharma AG, Biostatistics & Statistical Reporting, CH-4002 Basel, Switzerland
05.12.2022 at 4:15 p.m., TU Dortmund, CDI 120	Genotoxicity Assessments of Pharmaceuticals Prof. Dr. Helena Geys, Hasselt University, Belgium
28.11.2022 at 4:15 p.m., TU Dortmund, CDI 120	A novel group-sequential phase II design for clinical trials with binary endpoints based on Bayesian evidence values Dr. Riko Kelter, Department of Mathematics, Research Group Stochastics, University of Siegen
14.11.2022 at 4:15 p.m., via Zoom	A replication crisis in methodological statistical research? Prof. Dr. Anne-Laure Boulesteix, Institut für Medizinische Informationsverarbeitung Biometrie und Epidemiologie (IBE), Fakultät der LMU München
07.11.2022 at 4:15 p.m., TU Dortmund, CDI 120	Shinybrms and projpred: Introductory and advanced Bayesian (and not-so-Bayesian) statistics in practice Frank Weber, Institut für Biostatistik und Informatik in Medizin und Alternsforschung (IBIMA)
17.10.2022 at 4:15 p.m., TU Dortmund, CDI 120	Virtual Control Groups: Using historical toxicity data to replace control-group animals Alexander Gurjanov, PHD Student at Bayer Pharmaceuticals
23.09.2022 at 9:30 a.m., TU Dortmund, CDI 116 and via Zoom	Talk 1: An Intro to ToxicR and Bayesian Dose-Response Talk 2: Fast Bayesian Gaussian Process Regression Using Compression H-Matrices Matt Wheeler, Ph.D. National Institute of Environmental Health Sciences
29.08.2022 at 4:15 p.m., via Zoom	The Hazelwood Health study and other opportunities in Australia Prof. Michael Abramson, School of Public Health & Preventive Medicine, Monash University, Australia
04.07.2022 at 4:15 p.m., TU Dortmund, M/E 21 and via Zoom	Random forests on high-dimensional data: from classification and survival analysis to generative modelling Prof. Dr. Marvin N. Wright, Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS, Bremen
27.06.2022 at 4:15 p.m., TU Dortmund, M/E 21 and via Zoom	Issues in supervised prediction and classification for complex chemical substances Prof. Fred Wright, Ph.D., Departments of Statistics and Biological Sciences, North Carolina State University, USA
24.06.2022 at 12:00 p.m., TU Dortmund, M/E 21 and via Zoom	Modeling Heterogeneity for Stratified Populations Prof. Menggang Yu, Department of Biostatistics and Medical informatics, University of Wisconsin-Madison, USA
20.06.2022 at 4:15 p.m., via Zoom	Propensity Score: an Alternative Method of Analyzing Intervention Effect Prof. Dr. sc. hum. Oliver Kuß, Deutsches Diabetes-Zentrum, Düsseldorf
30.05.2022 at 4:15 p.m., via Zoom	Gene expression to Omics: The evolution of genetic research Ashtyn Areal, IUF Düsseldorf
23.05.2022 at 4:15 p.m., via Zoom	Analysis and design of clinical trials with biologics using dose-time-response models Markus Lange, Novartis
16.05.2022 at 4:15 p.m., via Zoom	The case time series design for high-dimensional data analyses Prof. Antonio Gasparrini, London School of Hygiene and Tropical Medicine, London, UK
09.05.2022 at 4:15 p.m., via Zoom	Mehrstadien-Modelle in der Epidemiologie chronischen Erkrankungen Prof. Dr. rer. nat. Ralph Brinks , Lehrstuhl für Medizinische Biometrie und Epidemiologie, Private Universität Witten/Herdecke gGmbH
14.02.2022 at 4:15 p.m., via Zoom	Assessing interactive effects of air pollution and temperature– approaches and challenges? Dr. Susanne Breitner , Helmholtz-Zentrum München
24.01.2022 at 4:15 p.m., via Zoom	Dose- response analysis in toxicology: considering dose both as qualitative factor and quantitative covariate (using R) Prof. Dr. Ludwig Hothorn, Biostatistician, Retired from Leibniz University Hannover
10.01.2022 at 4:15 p.m., via Zoom	Systems genetics strategies for describing the transcriptional connectome and it's role in complex traits Associate Professor Laura Saba, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, USA
06.12.2021 at 4:15 p.m., via Zoom	Can statistics save preclinical research? Prof. Dr. med. Ulrich Dirnagl, Abteilungsdirektor Experimentelle Neurologie, Charité Berlin
29.11.2021 at 4:15 p.m., via Zoom	Dose-response analysis for gene-expression data Scott S. Auerbach, PhD, und Matt Wheeler, PHD, Institute of Environmental Health Sciences, Durham, NC, USA Abstract
15.11.2021 at 4:15 p.m., via Zoom	Good Scientific Practise for Doctoral Researchers Dr. Peter Schröder, brain4hire, Graduiertenzentrum TU Dortmund
25.10.2021 at 4:15 p.m., via Zoom	Recent extensions on boosting for statistical modelling Prof. Dr. Andreas Mayr, Head of WG Statistical Methods in Epidemiology, Universität Bonn
05.08.2021 at 4:15 p.m., via Zoom	Polygenic risk scores – Applicability beyond risk prediction and for different omics data Anke Hüls, PhD, MSc, Assistant Professor, Department of Epidemiology and Gangarosa Department of Environmental Health, Emory University
28.06.2021 at 4:15 p.m., via Zoom	Advances in dose-response analysis Prof. Christian Ritz , National Institute of Public Health,Copenhagen

To be announced

To be announced

To be announced

(Joint) Modelling approaches for lung function decline and risk of death for cystic fibrosis patients

Multiple Endpoints and Prioritized Outcomes: Effects and Nonparametric Analysis Methods

Allelic expression imbalance to uncover disease-relevant gene regulation

Sample size planning for multiple contrast test

Phases of development for statistical methods

Methods for the meta-analysis of ROC curves – A statistical challenge

Insights into the world of a CMC statistician

Statistical Planning and Analysis of Translational Trials

How to better detect differentially expressed proteins when the sample size is small

Sparse group models for leveraging pleiotropy effects from GWAS

Talk 1: Use of Environmental Mixture Methodology in Epidemiology Studies Talk 2: Constructing DNA methylation risk scores for mediation analysis

Talk 1: EFSA’s guidance on the use of the BMD approach in risk assessment Talk 2: The statistical methodology behind EFSA’s BMD platform Talk 3: Illustration of EFSA’s new BMD analysis platform

Efficient Designs for toxicological experiments

How does air pollution effect our brain? The complex relationship between environmental, social and epigenetic factors?

Anke Huels, Assistant Professor, Department of Epidemiology and Gangarosa Departmentof Environmental Health, Rollins School of Public Health, Emory University, Atlanta, USA

Prediction Intervals for overdispersed Poisson data

Novel clinical trial designs for precision oncology:

Optimal test procedures for multiple hypotheses controlling the familywise expected loss

Genotoxicity Assessments of Pharmaceuticals

A novel group-sequential phase II design for clinical trials with binary endpoints based on Bayesian evidence values

A replication crisis in methodological statistical research?

Shinybrms and projpred: Introductory and advanced Bayesian (and not-so-Bayesian) statistics in practice

Virtual Control Groups: Using historical toxicity data to replace control-group animals

Talk 1: An Intro to ToxicR and Bayesian Dose-Response Talk 2: Fast Bayesian Gaussian Process Regression Using Compression H-Matrices

The Hazelwood Health study and other opportunities in Australia

Random forests on high-dimensional data: from classification and survival analysis to generative modelling

Issues in supervised prediction and classification for complex chemical substances

Modeling Heterogeneity for Stratified Populations

Propensity Score: an Alternative Method of Analyzing Intervention Effect

Gene expression to Omics: The evolution of genetic research

Analysis and design of clinical trials with biologics using dose-time-response models

The case time series design for high-dimensional data analyses

Mehrstadien-Modelle in der Epidemiologie chronischen Erkrankungen

Assessing interactive effects of air pollution and temperature– approaches and challenges?

Dose- response analysis in toxicology: considering dose both as qualitative factor and quantitative covariate (using R)

Systems genetics strategies for describing the transcriptional connectome and it's role in complex traits

Can statistics save preclinical research?

Dose-response analysis for gene-expression data

Good Scientific Practise for Doctoral Researchers

Recent extensions on boosting for statistical modelling

Polygenic risk scores – Applicability beyond risk prediction and for different omics data

Advances in dose-response analysis

Talk 1: Use of Environmental Mixture Methodology in Epidemiology Studies
Talk 2: Constructing DNA methylation risk scores for mediation analysis

Talk 1: EFSA’s guidance on the use of the BMD approach in risk assessment
Talk 2: The statistical methodology behind EFSA’s BMD platform
Talk 3: Illustration of EFSA’s new BMD analysis platform

Talk 1: An Intro to ToxicR and Bayesian Dose-Response
Talk 2: Fast Bayesian Gaussian Process Regression Using Compression H-Matrices